Dr. Guy F Webster , MD, PhD
Dermatology • Hockessin, DE
720 Yorklyn Rd, Suite 10
Hockessin, DE 197078728
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on September 28, 2006; this date does not establish years in practice.
-
Published CMS data list 5,545 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- 17003 — Destruction of precancer skin growth, 2-14 growths: 1,835 service units.
- 99213 — Established patient outpatient office visit: 1,531 service units.
- 17000 — Destruction of precancer skin growth, 1 growth: 822 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 13 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 977 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Betamethasone Diprop Augmented (Betamethasone/Propylene Glyc) — 124 prescription fills, including refills.
- Triamcinolone Acetonide — 105 prescription fills, including refills.
- Mometasone Furoate — 102 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 21 records in the table · Guide: How to read Medicare Part D prescriber data
-
Close to the middle for Medicare Part B services among clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: 5,705. Middle half: 4,317 to 14,070.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 7,291 in 2020 to 5,545 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
720 Yorklyn Rd
Suite 10
Hockessin, DE 197078728
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
CMS Doctors and Clinicians lists 1 group name: Zitelli And Brodland Pc. See the list
Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
Perelman School Of Med At The University Of Pennsylvania
1985
What Public CMS Data Show
Dermatology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
1,720 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $360,401 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $242,068 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
1,218 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$887,007 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $1,649.84 across 85 records.
By nature of payment
- Food and Beverage: $1,649.84 across 85 records.
Reporting-company totals (3 largest of 18)
- Janssen Pharmaceuticals, Inc: $273.16 across 13 records.
- ABBVIE INC.: $173.52 across 12 records.
- Eli Lilly and Company: $172.20 across 8 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
41 years (graduated 1985)
CMS Doctors and Clinicians data list 1985 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2006
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Webster has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Webster as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Hockessin and Delaware
Billing and prescribing volume is not a quality rating.
Medicare Part B services
Close to the middle for clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: 5,705. Middle half: 4,317 to 14,070.
Too few clinicians listed under Dermatology in Hockessin have Medicare Part B data for 2024 to compare.
Medicare-allowed amount
Close to the middle for clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: $369,680. Middle half: $269,274 to $803,710.
Too few clinicians listed under Dermatology in Hockessin have Medicare Part B data for 2024 to compare.
Paid by Medicare
Close to the middle for clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: $254,428. Middle half: $189,411 to $591,925.
Too few clinicians listed under Dermatology in Hockessin have Medicare Part B data for 2024 to compare.
Medicare Part D prescriptions
Close to the middle for clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: 1,044. Middle half: 729 to 1,526.
Too few clinicians listed under Dermatology in Hockessin have Medicare Part D data for 2024 to compare.
Part D drug cost
A higher Part D drug cost than 80% of clinicians listed under Dermatology in Delaware (2024, 18 clinicians with data). Median for this group: $372,196. Middle half: $99,447 to $769,962.
Too few clinicians listed under Dermatology in Hockessin have Medicare Part D data for 2024 to compare.
3 active clinicians are listed under Dermatology with a practice address in Hockessin, DE (27 in Delaware).
Addresses are self-reported to NPPES and may be out of date.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services decreased 24% from 7,291 in 2020 to 5,545 in 2024.
- 2020: 7,291
- 2021: 8,413
- 2022: 6,873
- 2023: 6,405
- 2024: 5,545
-
Medicare-allowed amount
Medicare-allowed amount stayed about the same: $387,632 in 2020 and $360,401 in 2024.
- 2020: $387,632
- 2021: $467,536
- 2022: $410,566
- 2023: $413,962
- 2024: $360,401
-
Paid by Medicare
Paid by Medicare stayed about the same: $266,920 in 2020 and $242,068 in 2024.
- 2020: $266,920
- 2021: $318,471
- 2022: $269,074
- 2023: $283,167
- 2024: $242,068
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 15% from 847 in 2020 to 977 in 2024.
- 2020: 847
- 2021: 943
- 2022: 840
- 2023: 892
- 2024: 977
-
30-day fills
30-day fills increased 12% from 1,087 in 2020 to 1,218 in 2024.
- 2020: 1,087
- 2021: 1,222
- 2022: 1,113
- 2023: 1,116
- 2024: 1,218
-
Part D drug cost
Part D drug cost increased 313% from $214,585 in 2020 to $887,007 in 2024.
- 2020: $214,585
- 2021: $523,827
- 2022: $453,850
- 2023: $651,172
- 2024: $887,007
-
Industry payments (Open Payments)
Industry payments (Open Payments) decreased 80% from $8,300.73 in 2021 to $1,649.84 in 2025.
- 2021: $8,300.73
- 2022: $1,071.02
- 2023: $4,002.35
- 2024: $1,477.44
- 2025: $1,649.84
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 85 records totaling $1,649.84.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. |
Food and Beverage
In-kind items and services
|
Zoryve | General | $97.13 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
TREMFYA | General | $38.26 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
TREMFYA | General | $36.16 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
TREMFYA | General | $35.69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
SPEVIGO | General | $33.38 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
TREMFYA | General | $29.13 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $28.72 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $25.84 |
| Pfizer Inc. |
Food and Beverage
In-kind items and services
|
CIBINQO | General | $25.69 |
| Pfizer Inc. |
Food and Beverage
In-kind items and services
|
CIBINQO | General | $25.28 |
| Almirall LLC |
Food and Beverage
In-kind items and services
|
Klisyri | General | $25.24 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $24.65 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $24.26 |
| Incyte Corporation |
Food and Beverage
Cash or cash equivalent
|
OPZELURA | General | $24.24 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $24.22 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
Leqselvi | General | $24.05 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
Rhapsido | General | $23.11 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $23.03 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $23.00 |
| Boehringer Ingelheim Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
SPEVIGO | General | $22.70 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $22.65 |
| Organon LLC |
Food and Beverage
In-kind items and services
|
— | General | $22.39 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $22.27 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $21.76 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $21.72 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
17003
Destruction of precancer skin growth, 2-14 growths
|
1,835 | 464 | $19.82 | $6.58 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
1,531 | 1,247 | $271.36 | $89.94 |
|
17000
Destruction of precancer skin growth, 1 growth
|
822 | 683 | $202.17 | $62.43 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
529 | 426 | $382.80 | $127.03 |
|
11102
Biopsy of related skin growth, first growth
|
308 | 271 | $298.95 | $96.61 |
|
17110
Destruction of skin growth, 1-14 growths
|
232 | 224 | $339.84 | $111.24 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
135 | 135 | $333.13 | $110.13 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
45 | 45 | $499.94 | $162.58 |
|
17262
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm
|
35 | 31 | $533.24 | $169.27 |
|
11103
Biopsy of related skin growth, each additional growth
|
26 | 22 | $149.30 | $49.49 |
|
17261
Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm
|
19 | 19 | $443.79 | $127.81 |
|
17004
Destruction of precancer skin growth, 15 or more growths
|
14 | 12 | $499.80 | $165.56 |
|
17281
Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm
|
14 | 13 | $538.21 | $171.98 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 124 | 2,995 | $1,523.93 | 69 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 2,705 | $736.97 | 72 |
| Mometasone Furoate | Mometasone Furoate | 102 | 2,749 | $1,997.47 | 74 |
| Doxycycline Hyclate | Doxycycline Hyclate | 101 | 6,183 | $3,762.21 | 50 |
| Ciclopirox | Ciclopirox Olamine | 84 | 2,326 | $1,039.00 | 59 |
| Clobetasol Propionate | Clobetasol Propionate | 72 | 2,090 | $4,377.67 | 44 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 67 | 1,990 | $3,460.73 | 27 |
| Dupixent Pen | Dupilumab | 49 | 1,358 | $186,760.64 | — |
| Metronidazole | Metronidazole | 35 | 970 | $1,555.46 | 23 |
| Humira(Cf) Pen | Adalimumab | 33 | 910 | $250,432.86 | — |
| Prednisone | Prednisone | 32 | 938 | $88.22 | 18 |
| Fluorouracil | Fluorouracil | 32 | 960 | $1,869.02 | 32 |
| Hydrocortisone | Hydrocortisone | 21 | 499 | $121.16 | 12 |
| Valacyclovir | Valacyclovir Hcl | 20 | 555 | $288.01 | 11 |
| Stelara | Ustekinumab | 18 | 1,464 | $277,978.38 | — |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | 1,295 | $1,423.94 | — |
| Imiquimod | Imiquimod | 15 | 361 | $226.59 | 15 |
| Dupixent Syringe | Dupilumab | 14 | 392 | $53,691.82 | — |
| Enbrel | Etanercept | 13 | 364 | $92,787.90 | — |
| Fluconazole | Fluconazole | 12 | 669 | $397.71 | — |
| Tacrolimus | Tacrolimus | 12 | 360 | $2,486.84 | — |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
NUCC Taxonomy Code: 207N00000X
A dermatologist is trained to diagnose and treat pediatric and adult patients with benign and malignant disorders of the skin, mouth, external genitalia, hair and nails, as well as a number of sexually transmitted diseases. The dermatologist has had additional training and experience in the diagnosis and treatment of skin cancers, melanomas, moles and other tumors of the skin, the management of contact dermatitis and other allergic and nonallergic skin disorders, and in the recognition of the skin manifestations of systemic (including internal malignancy) and infectious diseases. Dermatologists have special training in dermatopathology and in the surgical techniques used in dermatology. They also have expertise in the management of cosmetic disorders of the skin such as hair loss and scars and the skin changes associated with aging.
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - DERMATOLOGY
I20050323001398
DE
5092772764
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File
Zitelli And Brodland Pc
720 Yorklyn Rd, Hockessin, DE 197078730
Phone: 3022349305
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Nurse Practitioner - Family
Dermatology
Doctor of Medicine (M.D.)
Career & Practice History
NPI enumerated September 28, 2006.
No changes to the name, practice address, taxonomy or NPI status in this record have been observed in the monthly NPPES data files from January 2017 to August 2026.
NPI Administrative Meta
Other Dermatology Specialists in Hockessin
Healthcare providers in HockessinMailing Address
720 Yorklyn Rd, Suite 10
Hockessin, DE 197078728
Phone: 3022349305